(UroToday.com) Active surveillance aims to reduce overtreatment in patients with low-risk prostate cancer and has, as initial treatment, excellent prostate cancer-specific survival.1-2 The reduction of overtreatment is, however, limited due to a high rate of discontinuation.3 Magnetic resonance imaging (MRI) enables a more accurate sampling of prostate cancer, and the use of MRI before inclusion in active surveillance should, therefore, reduce lead to less discontinuation of active surveillance. Furthermore, the use of MRI in active surveillance algorithms is strongly supported by the European Association of Urology.4  At the American Urological Association (AUA) 2020 virtual annual meeting, Dr. Monique Roobol and colleagues presented results of their study comparing the rate of active surveillance discontinuation of men included with and without MRI information at inclusion.